IDEXX Laboratories Taking Pre-orders for the SNAP Pro Mobile Device

The SNAP Pro device automates the SNAP test, eliminates lost charges and ensures that SNAP results are instantaneously available to practitioners; product shipment is expected in Q1 2014.

WESTBROOK, Maine, November 14, 2013—IDEXX Laboratories introduces the latest innovation in rapid point-of-care diagnostic testing, the SNAP Pro Mobile Device, and has begun taking pre-orders in North America with device shipments anticipated by late first quarter, 2014. The SNAP Pro device is an advanced point-of-care instrument that automatically activates SNAP tests, captures and saves images of the results and records invoice charges in the patient record.

IDEXX SNAP tests are the most trusted point-of-care diagnostics in the industry. Tens of thousands of veterinary professionals worldwide use SNAP tests to help diagnose a broad range of canine and feline diseases including heartworm, tick-borne diseases (Lyme disease, anaplasmosis, ehrlichiosis), pancreatitis, cardiac issues and others. Building on that platform, the SNAP Pro device leverages the latest in mobile computing technologies, including a smartphone-like footprint, a dynamic touch screen and cloud computing.

“The immediate, accurate results provided by SNAP tests are an essential part of everyday diagnostic protocols for tens of thousands of practices worldwide,” said Dana Belisle, Vice President and General Manager, IDEXX Rapid Assay. “Adding the SNAP Pro Mobile Device to established protocols significantly improves practice efficiency by automating the entire SNAP test process.”

Belisle continued, “At the touch of a button, the SNAP Pro device activates a test, times the run and electronically captures an image of the test result, which can then be shared with clients. And equally important, the SNAP Pro device helps significantly reduce lost invoice charges by automatically capturing the test run in the practice management system.”

Highlights of the SNAP Pro Mobile Device:

  • Fast and easy to use. A technician or doctor inserts the SNAP test, and the device automatically activates the test, properly times the run and captures an image of the result. Users can share the results on the SNAP Pro screen or via VetConnect PLUS.
  • Improves staff efficiency and saves practices money by ensuring all SNAP test runs are captured and entered into the patient record.
  • Populates VetConnect PLUS with additional diagnostic results and further establishes that platform as the most comprehensive portal to a patient’s diagnostic history.

“The SNAP Pro Mobile Device is an ideal tool for engaging pet owners and an invaluable visual aid when explaining the need for additional diagnostics or when trying to gain client compliance with recommendations,” concluded Belisle.

IDEXX is accepting pre-orders for the SNAP Pro Mobile Device, which will be available for shipment later in Q1 2014. Practices interested in the SNAP Pro device can schedule a demonstration and learn more at idexx.com/snappro or by contacting your IDEXX sales representative or authorized distributor representative.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,500 people and offers products to customers in more than 175 countries.

Note Regarding Forward-Looking Statements
This press release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the Company’s ability to manufacture complex biologic products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the impact of distributor purchasing decisions on sales of the Company’s products that are sold through distribution; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the effects of interruptions to the Company’s operations due to natural disasters or system failures. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States and via the Company's website at www.idexx.com).


Contact:

IDEXX Laboratories
David Eaton
Senior Programs Manager, Direct Marketing
1-207-318-1352
david-eaton@idexx.com